DataMEDS AI Buys Helomics, Adding a Certified Cancer Laboratory

DataMEDS AI has completed its purchase of Helomics from Axe Compute, gaining a certified oncology laboratory, laboratory equipment and contract-research services as it moves into cancer diagnostics. The stated purchase value was $1.5 million in DataMEDS common shares and an acquisition note; the buyer also received $1.5 million in cash.

A deal that changes the operating base

The company disclosed the completed transaction on September 15. It takes DataMEDS beyond its existing pharmacy, data and healthcare-technology activities into cancer management and precision oncology, according to the companies’ descriptions of the deal.

The structure is unusual on its face: DataMEDS put the purchase value at $1.5 million, paid through shares and a note, while saying it received the same amount of cash with the acquired business. The companies have not disclosed the number of shares, the note’s terms or its repayment schedule.

Assets now, a broader service plan later

Helomics brings a CLIA/CAP-certified clinical laboratory and associated equipment, along with Predictive Oncology’s contract research organization central-laboratory services business. That gives DataMEDS operating infrastructure rather than only a plan to build one.

What DataMEDS says came with Helomics

• A CLIA/CAP-certified clinical laboratory and related equipment.
• Predictive Oncology’s contract research organization central-laboratory services business.
• No third-party debt requiring repayment or overdue accounts payable beyond ongoing monthly operating expenses, according to the transaction description.

DataMEDS plans to use the business for cancer screening, broader molecular profiling, traditional clinical laboratory services and nutritional support for cancer patients. Those are plans for expansion, not reported commercial results or a disclosed rollout timetable.

The next test is integration

For Axe Compute, the sale completes its exit from remaining cancer-testing operations. It will still hold DataMEDS shares received as consideration, preserving an indirect link to the business it sold.

The immediate strategic case is clear: DataMEDS now owns a laboratory and services business it can try to extend into more oncology offerings. The harder questions remain financial and operational. Neither company disclosed Helomics’ current revenue, profitability or expected earnings contribution, leaving the value of the acquired operation and the demands of integrating it unresolved.